S. Mather

发表

Length-dependent retention of carbon nanotubes in the pleural space of mice initiates sustained inflammation and progressive fibrosis on the parietal pleura.

Antonio Nunes, Stephen J Mather, Adriele Prina-Mello, 2011, The American journal of pathology.

99mTc-HYNIC-Gastrin Peptides: Assisted Coordination of 99mTc by Amino Acid Side Chains Results in Improved Performance Both In Vitro and In Vivo

C. Finucane, S. Mather, P. Blower, 2009, Journal of Nuclear Medicine.

Targeting of CCK-2 Receptor–Expressing Tumors Using a Radiolabeled Divalent Gastrin Peptide

S. Watson, C. Finucane, S. Mather, 2009, Journal of Nuclear Medicine.

Insertion of a lysosomal enzyme cleavage site into the sequence of a radiolabeled neuropeptide influences cell trafficking in vitro and in vivo.

C. Finucane, S. Mather, J. Sosabowski, 2010, Cancer biotherapy & radiopharmaceuticals.

High-throughput high-volume nuclear imaging for preclinical in vivo compound screening§

C. Finucane, S. Mather, S. Macholl, 2017, EJNMMI Research.

GRP Receptor Imaging of Prostate Cancer Using [99mTc]Demobesin 4: a First-in-Man Study

N. Avril, T. Powles, S. Mather, 2014, Molecular Imaging and Biology.

Degree of chemical functionalization of carbon nanotubes determines tissue distribution and excretion profile.

F. Toma, M. Prato, M. Herrero, 2012, Angewandte Chemie.

Recombinant human VEGF165b protein is an effective anti-cancer agent in mice.

Maryam Hamdollah-Zadeh, S. Harper, D. Bates, 2008, European journal of cancer.

Radiolabelled interleukin 2 for in vivo imaging of activated T-lymphocytes

Barone, S. Calvieri, S. Mather, 2017 .

99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study.

S. Calvieri, S. Mather, A. Signore, 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Targeting prostate cancer with radiolabelled bombesins

S. Mather, B. Nock, T. Maina, 2006, Cancer imaging : the official publication of the International Cancer Imaging Society.

The relationship between the diameter of chemically-functionalized multi-walled carbon nanotubes and their organ biodistribution profiles in vivo.

M. Prato, A. Bianco, M. Robinson, 2014, Biomaterials.

Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes

S. Mather, J. Sosabowski, 2006, Nature Protocols.

Molecular imaging of inflammation/infection: nuclear medicine and optical imaging agents and methods.

G. Piaggio, R. Dierckx, S. Mather, 2010, Chemical reviews.

PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In.

W. Oyen, C. Hudson, S. Mather, 2014, Molecular pharmaceutics.

Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation.

M. Ocak, S. Mather, C. Decristoforo, 2009, Journal of medicinal chemistry.

Conjugation of chelating agents to proteins and radiolabeling with trivalent metallic isotopes

Stephen J Mather, S. Mather, M. Cooper, 2006, Nature Protocols.

Automated radiolabelling of monoclonal antibodies with the Modular Lab system

S. Mather, D. Ellison, J. Kaufman, 2010, Nuclear medicine communications.

A novel model for the pre-clinical imaging of inflamed human synovial vasculature.

S. Mather, C. Pitzalis, D. Haskard, 2009, Rheumatology.

Radiolabelling of monoclonal antibodies.

S. Mather, D. Ellison, 1994, Nuclear medicine communications.

Labelling monoclonal antibodies with Yttrium-90

S. Mather, David M. Tolley, G. White, 2004, European Journal of Nuclear Medicine.

Current Directions in Radiopharmaceutical Research and Development

S. Mather, 2011, Developments in Nuclear Medicine.

Design of radiolabelled ligands for the imaging and treatment of cancer.

S. Mather, 2007, Molecular bioSystems.

Disturbed gastric and small bowel transit in severe idiopathic constipation

M. Kamm, J. Lennard-jones, L. Akkermans, 1993, Digestive Diseases and Sciences.

VEGF121b, a new member of the VEGFxxxb family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo

D. Bates, A. Varey, S. Mather, 2009, British Journal of Cancer.

Chimeric Antigen Receptor aTumor-Associated MUC 1 : The Evolution of Retargeting of Human T Cells to Burchell and

J. Taylor‐Papadimitriou, S. Mather, J. Maher, 2008 .

Trafficking of CAR-Engineered Human T Cells Following Regional or Systemic Adoptive Transfer in SCID Beige Mice

S. Mather, J. Maher, J. Burnet, 2011, Journal of Clinical Immunology.

Molecular imaging with bioconjugates in mouse models of cancer.

S. Mather, 2009, Bioconjugate chemistry.

99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives

R. Moncayo, S. Mather, E. Donnemiller, 2000, European Journal of Nuclear Medicine.

An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.

H. Ulmer, R. Moncayo, S. Mather, 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

99mTCHyNIC [Tyr3]-Octreotide for Imaging Somatostatin-Receptorâ€”Positive Tumors: Preclinical Evaluation and Comparison with 11n-Octreotide

S. Mather, C. Decristoforo, J. Sosabowski, 2006 .

Optimization of the small-scale synthesis of DOTA-Tyr3-octreotide

S. Mather, L. Meléndez-Alafort, M. Edreira, 2002, Nuclear medicine communications.

42. Imaging somatostatin receptor-positive neoplasms (SRPN) and their metastases with radiolabelled somatostatin analogues 123I Tyr-3-octreotide (TOCT) and 111In [DTPA-D-Phe1]-octreotide (DOCT)

A. Grossman, S. Mather, J. Bomanji, 1992 .

Pituitary imaging using a labelled somatostatin analogue in acromegaly

S. Mather, A. Grossman, J. Bomanji, 1992, Clinical endocrinology.

Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumors

W. Bodmer, R. Poulsom, M. Ilyas, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Radiolabelling of glycosylated MFE-23::CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT)

S. Sharma, S. Mather, R. Begent, 2004, European Journal of Nuclear Medicine and Molecular Imaging.

Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration.

M. Slevin, J. Shepherd, S. Mather, 1987, Cancer research.

99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide.

S. Mather, C. Decristoforo, J. Sosabowski, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A cross-linked monoclonal antibody fragment for improved tumor targeting.

M. Stalteri, S. Mather, 1995, Bioconjugate chemistry.

Pancreatic scintigraphy with 99mTc‐interleukin‐2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy

S. Mather, A. Signore, P. Pozzilli, 2008, Diabetes/metabolism research and reviews.

TARGETING OF IODINE-123-LABELLED TUMOUR-ASSOCIATED MONOCLONAL ANTIBODIES TO OVARIAN, BREAST, AND GASTROINTESTINAL TUMOURS

W. Bodmer, J. Taylor‐Papadimitriou, S. Mather, 1982, The Lancet.

99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution.

S. Mather, C. Decristoforo, Stephen J. Mather, 1999, Nuclear medicine and biology.

Radioiodinated monoclonal antibodies.

S. Mather, 1988, The International journal of biochemistry.

Radioiodinated monoclonal antibodies: a critical review.

S. Mather, 1986, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

High efficiency iodination of monoclonal antibodies for radiotherapy.

S. Mather, B. G. Ward, 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Diagnostic evaluation of 111In and 99mTc radiolabelled monoclonal antibodies in ovarian and colorectal cancer: correlations with surgery.

S. Mather, K. Britton, M. Granowska, 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Diagnosis of ovarian cancer with radiolabelled antibodies.

S. Mather, K. Britton, C. Nimmon, 1989, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

123I radioiodinated antibody imaging of occult ovarian cancer

W. Bodmer, J. Taylor‐Papadimitriou, J. Shepherd, 1985, Cancer.

Pathogen identification by nuclear imaging – almost there?

S. Mather, S. Agrawal, 2012, European Journal of Nuclear Medicine and Molecular Imaging.

Animal Models for Developing Radiopharmaceuticals for Therapy

M. Jong, S. Mather, T. Maina, 2012 .

Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer

J. Taylor‐Papadimitriou, D. Lowe, J. Shepherd, 1993, European Journal of Nuclear Medicine.

High‐resolution in vivo imaging of breast cancer by targeting the pro‐invasive integrin αvβ6

G. Thomas, S. Mather, I. Hart, 2010, The Journal of pathology.

Potentiated by Liposomal Alendronic Acid 2 T Cells, d 9V g Ovarian Cancer with V Adoptive Immunotherapy of Epithelial

H. Shmeeda, A. Gabizon, Sadaf, 2014 .

Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence

S. Mather, C. Decristoforo, 1999, European Journal of Nuclear Medicine.

Trifluoroacetyl as a protecting group for HYNIC: stability in the presence of electrophiles and application in the synthesis of 99mTc-radiolabelled peptides

S. Mather, P. Blower, R. King, 2010 .

Synthesis and Optimization of the Labeling Procedure of 99mTc-Hynic-Interleukin-2 for In vivo Imaging of Activated T lymphocytes

S. Mather, A. Signore, M. Chianelli, 2009, Molecular Imaging and Biology.

Technetium-binding in labelled HYNIC-peptide conjugates: role of coordinating amino acids.

S. Mather, P. Blower, R. King, 2009, Journal of inorganic biochemistry.

How do HYNIC-conjugated peptides bind technetium? Insights from LC-MS and stability studies.

S. Mather, P. Blower, R. King, 2007, Dalton transactions.

Synthesis of 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes

B. Cornelissen, R. Dierckx, S. Mather, 2006, European Journal of Nuclear Medicine and Molecular Imaging.

Hybridization and cell uptake studies with radiolabelled antisense oligonucleotides

M. Stalteri, S. Mather, 2001, Nuclear medicine communications.

188Rhenium‐labelling of hynic‐[Tyr3]octreotide

S. Mather, L. Meléndez-Alafort, 2001 .

A prospective study of 123I-labeled monoclonal antibody imaging in ovarian cancer.

M. Slevin, R. Osborne, J. Shepherd, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ovarian cancer: diagnosis using 123I monoclonal antibody in comparison with surgical findings.

J. Taylor‐Papadimitriou, J. Shepherd, S. Mather, 1984, Nuclear medicine communications.

Radioimmunodiagnosis of ovarian cancer using 123I-labelled, tumor-associated monoclonal antibodies.

J. Taylor‐Papadimitriou, S. Mather, J. Malpas, 1984, Cancer detection and prevention.

Progress in Radiopharmacy

P. H. Cox, S. Mather, C. Lazarus, 2011, Developments in Nuclear Medicine.

Radiolabelled Antibodies as Radiopharmaceuticals

S. Mather, 1986 .

Reduction-mediated technetium-99m labeling of monoclonal antibodies.

S. Mather, D. Ellison, 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Labelling with Indium-111

S. Mather, 1987 .

The mechanism of hepatic uptake of a radiolabelled monoclonal antibody

S. Mather, C. C. Boyle, A. Paine, 1992, International journal of cancer.

99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience

J. Fettich, S. Mather, I. Mlinarič-Raščan, 2008, Nuclear medicine communications.

VirRAD — a “virtual” radiopharmacy learning community: your input needed

S. Mather, 2002, European Journal of Nuclear Medicine and Molecular Imaging.

188Re(CO)3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases.

C. Finucane, S. Mather, P. Blower, 2010, Bioconjugate chemistry.

Targeted delivery of anti-inflammatory therapy to rheumatoid tissue by fusion proteins containing an IL-4-linked synovial targeting peptide

C. Finucane, Y. Chernajovsky, S. Mather, 2011 .

Recent Advances in the Use of Radiolabelled Monoclonal Antibodies in the Management of Ovarian Cancer

J. Shepherd, S. Mather, K. Britton, 1991 .

Radiolabelling of peptides for diagnosis and therapy of non-oncological diseases.

S. Mather, L. Meléndez-Alafort, J. Sosabowsky, 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

Development of a novel recombinant biotherapeutic with applications in targeted therapy of human arthritis.

C. Finucane, S. Mather, Malcolm D. Smith, 2011, Arthritis and rheumatism.

Disturbed gastric emptying in the short bowel syndrome. Evidence for a 'colonic brake'.

M. Kamm, J. Lennard-jones, S. Mather, 1993, Gut.

99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study

A. Grossman, S. Mather, A. Signore, 2008, European Journal of Nuclear Medicine and Molecular Imaging.

The development of technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases.

S. Mather, A. Signore, M. Chianelli, 1997, Nuclear medicine and biology.

Structural Guided Scaffold Phage Display Libraries as a Source of Bio-Therapeutics

M. Howard, S. Mather, J. Marshall, 2013, PloS one.

99mTc-labelled SM3 in the preoperative evaluation of axillary lymph nodes and primary breast cancer with change detection statistical processing as an aid to tumour detection.

C. Wells, S. Mather, D. Ellison, 1998, British Journal of Cancer.

Selection of Radiolabeled Gastrin Analogs for Peptide Receptor–Targeted Radionuclide Therapy

S. Watson, S. Mather, A. McKenzie, 2007, Journal of Nuclear Medicine.

Pharmacokinetics and renal handling of 99mTc-labeled peptides.

S. Mather, A. Lázníčková, M. Lázníček, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Preparation, 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3]octreotide.

S. Mather, C. Decristoforo, Stephen J. Mather, 1999, Bioconjugate chemistry.

Analysis of accumulation of 99mTc-octreotide and 99mTc-EDDA/HYNIC-Tyr3-octreotide in the rat kidneys.

S. Mather, C. Decristoforo, A. Lázníčková, 2004, Nuclear medicine and biology.

Novel preparation and characterization of a trastuzumab–streptavidin conjugate for pre-targeted radionuclide therapy

S. Mather, P. Harrison, J. Hainsworth, 2006, Nuclear medicine communications.

General aspects of the cellular response to low- and high-LET radiation

S. Mather, J. Pouget, 2001, European Journal of Nuclear Medicine.

The influence of chelator on the pharmacokinetics of 99mTc-labelled peptides.

S. Mather, C. Decristoforo, 2002, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

Generation and Characterization of a Diabody Targeting the a v b 6 Integrin

K. Chester, G. Thomas, S. Mather, 2016 .

Generation and Characterization of a Diabody Targeting the αvβ6 Integrin

T. Meyer, K. Chester, G. Thomas, 2013, PloS one.

Radioiodination of Antibodies

S. Mather, 2006 .

Targeted delivery of cytokine therapy to rheumatoid tissue by a synovial targeting peptide

C. Finucane, Y. Chernajovsky, S. Mather, 2012, Annals of the rheumatic diseases.

New single-photon radiopharmaceuticals

S. Mather, 2006 .

Bioluminescence imaging of the brain response to acute inflammation in living C/EBP reporter mice

S. Mather, J. Foster, C. Magoulas, 2011, Neuroscience Letters.

Monitoring the in vivo behaviour of immunoglobulins with radiotracers: imaging approaches and data processing techniques.

S. Mather, K. Britton, C. Nimmon, 1989, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Radiolabelled monoclonal antibodies in oncology. I. Technical aspects.

S. Mather, K. Britton, M. Granowska, 1991, Nuclear medicine communications.

Technetium-99m labelling of the anti-tumour antibody PR1A3 by photoactivation

M. Stalteri, S. Mather, 1996, European Journal of Nuclear Medicine.

Bifunctional bisphosphonate complexes for the diagnosis and therapy of bone metastases.

S. Mather, P. Blower, C. Finucane, 2009, Chemical communications.

Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor1

Sylvain Julien, John Maher, J. Taylor‐Papadimitriou, 2008, The Journal of Immunology.

Kinetic analysis and probability mapping applied to the detection of ovarian cancer by radioimmunoscintigraphy.

K E Britton, M Granowska, M. Slevin, 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radiolabelled Stripped Mucin, SM3, Monoclonal Antibody for Immunoscintigraphy of Ovarian Tumours

S. Mather, K. Britton, T. Jobling, 1990, The International journal of biological markers.

Filled and glycosylated carbon nanotubes for in vivo radioemitter localization and imaging.

Malcolm L. H. Green, Stephen J Mather, Kostas Kostarelos, 2010, Nature materials.

Humanisation and characterisation of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigen

P. Bates, R. Wilkinson, S. Mather, 1999, Cancer Immunology, Immunotherapy.

A prospective study of radioimmunoscintigraphy in ovarian cancer

M. Slevin, J. Shepherd, S. Mather, 1985 .

Radiolabeled octreotide

S. Mather, J. Bomanji, D. Ellison, 1992, Cell Biophysics.

Identification of ZDHHC14 as a novel human tumour suppressor gene

D. Berney, Yong-jie Lu, D. Lin, 2014, The Journal of pathology.

Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.

T. Lister, J. Radford, A. Rohatiner, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A rapid method for the preparation of 99Tcm hexametazime-labelled leucocytes.

M. Janabi, S. Mather, K. Solanki, 1988, Nuclear medicine communications.

Radiopharmaceuticals for the study of inflammatory processes: a review.

S. Mather, A. Signore, M. Chianelli, 1997, Nuclear medicine communications.

Dynamic Imaging of Functionalized Multi‐Walled Carbon Nanotube Systemic Circulation and Urinary Excretion

Ande Bao, Maurizio Prato, Kostas Kostarelos, 2008 .

99mTc-interleukin-2 and 99mTc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease

S. Mather, A. Signore, R. Caprilli, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma

N. Avril, T. Hagemann, C. Hudson, 2014, Cell Death and Disease.

Flexible Targeting of ErbB Dimers That Drive Tumorigenesis by Using Genetically Engineered T Cells

S. Eccles, M. van Schalkwyk, S. Mather, 2012, Molecular medicine.

SPECT/CT imaging of oncolytic adenovirus propagation in tumours in vivo using the Na/I symporter as a reporter gene

K. Harrington, R. Iggo, G. Vassaux, 2007, Gene Therapy.

Neuroblastoma imaged with 123I meta-iodo-benzylguanidine and with 123I-labelled monoclonal antibody, UJ13A, against neural tissue.

S. Mather, J. Kemshead, J. Malpas, 1985, The British journal of radiology.

Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.

Yong-jie Lu, I. Tomlinson, B. Delage, 2014, Cancer research.

Axillary node status in breast cancer patients prior to surgery by imaging with Tc-99m humanised anti-PEM monoclonal antibody, hHMFG1

C. Wells, S. Mather, D. Ellison, 2002, British Journal of Cancer.

Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity?

S. Ghaem-Maghami, S. Mather, L. Whilding, 2013, The Journal of Immunology.

ErbB-Retargeted Human T Cells : Identifying Release Syndrome Induced by Preclinical In Vivo Modeling of Cytokine

S. Ghaem-Maghami, S. Mather, J. Maher, 2013 .

IAEA Technical Report Series

Luigi Mansi, L. Mansi, S. Mather, 2008, European Journal of Nuclear Medicine and Molecular Imaging.

Radioimmunoscintigraphy of Orbital Metastases from Ovarian Carcinoma

S. Mather, J. Bomanji, K. Britton, 1990, Clinical nuclear medicine.

22. High-voltage capillary electrophoresis: A new method for radiopharmaceutical analysis

S. Mather, 1997 .

Preparation via coligand exchange and characterization of [99mTc‐EDDA‐HYNIC‐D‐Phe1,Tyr3]Octreotide (99mTc–EDDA/HYNIC–TOC)

B. Sarg, H. Lindner, R. Moncayo, 2003 .

Radioisotope determination of regional colonic transit in severe constipation: comparison with radio opaque markers.

K E Britton, M. Kamm, J. Lennard-jones, 1993, Gut.

Imaging prostate cancer with technetium-99m-7E11-C5.3 (CYT-351).

M. Stalteri, R. Kirby, S. Mather, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radioimmunoscintigraphy of ovarian tumors using a new monoclonal antibody, SM-3.

D. Lowe, J. Shepherd, S. Mather, 1990, Gynecologic oncology.

Tumour‐associated monoclonal antibodies for the diagnosis and assessment of ovarian cancer

J. Shepherd, S. Mather, K. Britton, 1987, British journal of obstetrics and gynaecology.

Breast cancer 99mTc SM3 radioimmunoscintigraphy.

K E Britton, M Granowska, S. Mather, 1996, Acta oncologica.

Radioimmunoscintigraphy with technetium-99m labelled monoclonal antibody, 1A3, in colorectal cancer

I. Talbot, S. Mather, D. Ellison, 2004, European Journal of Nuclear Medicine.

Contrasting effects of sunitinib within in vivo models of metastasis

J. Erler, C. Springer, A. Reynolds, 2012, Angiogenesis.

Jonathan C. WeltiThomas PowlesShane FooMorgane Gourlaouen • Natasha PreeceJulie FosterSophia FrentzasDemelza BirdKevin Sharpe • Antoinette van WeverwijkDavid RobertsonJulie SoffeJanine T. Erler • Roberto PiliCaroline J. SpringerStephen J. MatherAndrew R. Reynolds

C. Springer, A. Reynolds, T. Powles, 2012 .

In vitro and in vivo comparison of DTPA- and DOTA-conjugated antiferritin monoclonal antibody for imaging and therapy of pancreatic cancer.

C. Finucane, S. Mather, D. Decaudin, 2007, Nuclear medicine and biology.

Quantitative Accuracy of Low-Count SPECT Imaging in Phantom and In Vivo Mouse Studies

C. Finucane, S. Mather, J. Sosabowski, 2011, International journal of molecular imaging.

99mTc radioimmunoscintigraphy of colorectal cancer.

S. Mather, P. Richman, K. Britton, 1990, The British journal of cancer. Supplement.

Evaluation of a transgenic mouse model for anti-human CEA radioimmunotherapeutics.

W. Zimmermann, R. Wilkinson, S. Mather, 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Identification of lymphatic spread of breast cancer using 99Tcm-labelled humanized anti-human milk fat globule (HHMFG) monoclonal antibody

C. Wells, S. Mather, D. Ellison, 1999 .

Contrasting effects of sunitinib within in vivo models of metastasis

J. Erler, C. Springer, A. Reynolds, 2012, Angiogenesis.

Magnetically Decorated Multiwalled Carbon Nanotubes as Dual MRI and SPECT Contrast Agents

A. Roig, G. van Tendeloo, X. Ke, 2014, Advanced functional materials.

Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging

A. Plückthun, T. Meyer, K. Chester, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

Radioiodinated recombinant human TSH: a novel radiopharmaceutical for thyroid cancer metastases detection.

B. Cornelissen, G. Slegers, C. Van de Wiele, 2004, Cancer biotherapy & radiopharmaceuticals.

Technetium: Chemistry and Radiopharmaceutical Applications.

S. Mather, 2001 .

Conjugation of chelating agents to proteins and radiolabeling with trivalent metallic isotopes

S. Mather, M. Cooper, Emmanuelle N. Sabbah, 2006, Nature Protocols.

Evaluation and comparison of a new DOTA and DTPA-bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor models.

K. Pasqualoto, C. Hudson, C. Finucane, 2015, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

RADIOLABELLED ANTIBODY FOR LOCALISING METASTASES

R. Coombes, A. Neville, S. Mather, 1983, The Lancet.

Cancer-specific transgene expression mediated by systemic injection of nanoparticles.

G. Vassaux, A. Schatzlein, I. Uchegbu, 2009, Cancer research.

Clinical experience with 99mTc-MAG3, mercaptoacetyltriglycine, and a comparison with 99mTc-DTPA

F. Fiore, S. Mather, J. Bomanji, 2004, European Journal of Nuclear Medicine.

A scintigraphic comparison of iodine-123-metaiodobenzylguanidine and an iodine-labeled somatostatin analog (Tyr-3-octreotide) in metastatic carcinoid tumors.

A. Grossman, S. Mather, J. Bomanji, 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

99Tc peptide-peptide nucleic acid probes for imaging oncogene mRNAs in tumours.

S. Mather, 2004, Nuclear medicine communications.

Radiolabelled cytokines.

S. Mather, M. Chianelli, 1996, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

FDG-PET and PET/CT in Breast Cancer Staging

N. Avril, R. Roylance, S. Mather, 2007, Breast Care.

99mTc-labeling and in vitro characterization of N4- and N3S-RGDS-derivative peptides

S. Mather, O. Reyes Acosta, D. Allison, 2008 .

Investigative clinical studies with radiopharmaceuticals.

S. Mather, K. Harding, 2007, Nuclear medicine communications.

Comparison of the stability of technetium-labeled peptides to challenge with cysteine.

M. Stalteri, S. Mather, R. Hider, 1999, Bioconjugate chemistry.

Prostatic radioimmunoscintigraphy: preliminary results using technetium-labelled monoclonal antibody, CYT-351.

R. Kirby, S. Mather, D. Ellison, 1996, British journal of urology.

99mTc Labelling of Interleukin-2 for in Vivo Targeting of Activated T-Lymphocytes

G. Ronga, S. Mather, A. Signore, 1994 .

99mTc-rituximab radiolabelled by photo-activation: a new non-Hodgkin’s lymphoma imaging agent

J. Fettich, S. Mather, I. Mlinarič-Raščan, 2005, European Journal of Nuclear Medicine and Molecular Imaging.

Radiopeptide internalisation and externalization assays: cell viability and radioligand integrity.

S. Mather, J. Sosabowski, T. Matzow, 2011, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

Trifluoroacetyl-HYNIC peptides: synthesis and 99mTc radiolabeling.

S. Mather, P. Blower, R. King, 2007, Journal of Medicinal Chemistry.

Solid phase synthesis of peptide radiopharmaceuticals using Fmoc-N-[omega]-(HYNIC-Boc)-lysine, a technetium-binding amino acid.

S. Mather, P. Blower, R. King, 2006 .

The design of a two‐phase radiolabelled meal for gastric emptying studies

M. Kamm, S. Mather, D. Ellison, 1991, Nuclear medicine communications.

Radiolabelled monoclonal antibodies in oncology. III. Radioimmunotherapy.

S. Mather, K. Britton, M. Granowska, 1991, Nuclear medicine communications.

Re: Controversies—[Tc(CO)3]+ chemistry: a promising new concept for SPET?

S. Mather, M. Cooper, J. Ballinger, 2004, European Journal of Nuclear Medicine and Molecular Imaging.

The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy.

M. Slevin, J. Shepherd, S. Mather, 1988, British Journal of Cancer.

Novel indium-111 labeled gastrin peptide analogues (MG-CL1-4): synthesis and quality control.

M. Yar, S. Mather, N. Mahmood, 2013, Pakistan journal of pharmaceutical sciences.

Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study.

S. A. Hagan, S. Watson, S. Mather, 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Photoreduction of monoclonal antibodies for conjugation and fragmentation.

M. Stalteri, S. Mather, D. Ellison, 2000, BioTechniques.

Bioluminescence imaging of the brain response to acute inflammation in living C/EBP reporter mice

S. Mather, J. Foster, C. Magoulas, 2011, Neuroscience Letters.

Magnetically Decorated Multiwalled Carbon Nanotubes as Dual MRI and SPECT Contrast Agents

A. Roig, G. van Tendeloo, X. Ke, 2014, Advanced functional materials.

Cancer-specific transgene expression mediated by systemic injection of nanoparticles.

G. Vassaux, A. Schatzlein, I. Uchegbu, 2009, Cancer research.

Site-specific conjugation and labelling of prostate antibody 7E11C5.3 (CYT 351) with technetium-99m

M. Stalteri, S. Mather, V. Chengazi, 1997, European Journal of Nuclear Medicine.

The relationship between the diameter of chemically-functionalized multi-walled carbon nanotubes and their organ biodistribution profiles in vivo.

M. Prato, A. Bianco, M. Robinson, 2014, Biomaterials.

Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.

I. Tomlinson, B. Delage, T. Crook, 2014, Cancer research.

Textbook of Radiopharmacy. Theory and Practice

S. Mather, 1992 .

Adoptive Immunotherapy of Epithelial Ovarian Cancer with Vγ9Vδ2 T Cells, Potentiated by Liposomal Alendronic Acid

H. Shmeeda, A. Gabizon, S. Ghaem-Maghami, 2014, The Journal of Immunology.